Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Marine compounds from gorgonians and soft corals show promise for drug development, especially for chronic disorders.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Blocking mTORC1 may help prevent skin cancer by stopping the growth of certain skin stem cells.

Reducing gefitinib dosage improved hair loss, but scarring remained.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Stopping mitochondrial respiration can prevent brain cancer spread in skin cancer patients, and plant compound β-sitosterol could help achieve this.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

JAK inhibitors are effective for long-term management of alopecia areata.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.

The microenvironment affects the behavior and survival of melanocytes with the GNAQ oncogene in melanoma.